{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:39Z","timestamp":1791273099432,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,20]]},"DOI":"10.1038\/s41416-026-03543-6","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:12:05Z","timestamp":1784812325000},"page":"1286-1297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-5630","authenticated-orcid":false,"given":"Paulina","family":"Czajka-Francuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-7153","authenticated-orcid":false,"given":"Chris","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8491","authenticated-orcid":false,"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Munje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksym","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalakrishnan","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Bohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmayee","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvarna","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7008","authenticated-orcid":false,"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Clack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-8429","authenticated-orcid":false,"given":"Debashis","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghib","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-3491","authenticated-orcid":false,"given":"Sarah P.","family":"Blagden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3309","authenticated-orcid":false,"given":"Kamal S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"3543_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/2229-3485.71839","volume":"1","author":"A Bhatt","year":"2010","unstructured":"Bhatt A. Evolution of clinical research: a history before and beyond james lind. Perspect Clin Res. 2010;1:6\u201310.","journal-title":"Perspect Clin Res"},{"key":"3543_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/014107680609901017","volume":"99","author":"J Crofton","year":"2006","unstructured":"Crofton J. The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line. J R Soc Med. 2006;99:531\u2013534. https:\/\/doi.org\/10.1177\/014107680609901017.","journal-title":"J R Soc Med"},{"key":"3543_CR3","doi-asserted-by":"crossref","unstructured":"Streptomycin Treatment of Pulmonary Tuberculosis. Br Med J. 1948;2:769\u2013782.","DOI":"10.1136\/bmj.2.4582.769"},{"key":"3543_CR4","doi-asserted-by":"publisher","unstructured":"Mahase E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. 2020; https:\/\/doi.org\/10.1136\/bmj.m4714.","DOI":"10.1136\/bmj.m4714"},{"key":"3543_CR5","unstructured":"Regulatory approval of Pfizer\/BioNTech vaccine for COVID-19. 2020. https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19 (Accessed 11 April 2026)."},{"key":"3543_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0262-4079(20)32148-5","volume":"248","author":"ML Page","year":"2020","unstructured":"Page ML. First shots given in the UK. N Sci. 2020;248:7 https:\/\/doi.org\/10.1016\/S0262-4079(20)32148-5.","journal-title":"N Sci"},{"key":"3543_CR7","unstructured":"Clinical Trials regulations signed into law. 2025. https:\/\/www.gov.uk\/government\/news\/clinical-trials-regulations-signed-into-law (Accessed 9 April 2026)."},{"key":"3543_CR8","doi-asserted-by":"publisher","first-page":"e000410","DOI":"10.1136\/bmjonc-2024-000410","volume":"3","author":"AD VanHelene","year":"2024","unstructured":"VanHelene AD, Hadfield MJ, Trapani D, Warner JL, Lythgoe MP. As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022. BMJ Oncol. 2024;3:e000410 https:\/\/doi.org\/10.1136\/bmjonc-2024-000410.","journal-title":"BMJ Oncol"},{"key":"3543_CR9","doi-asserted-by":"publisher","first-page":"o2540","DOI":"10.1136\/bmj.o2540","volume":"379","author":"E Mahase","year":"2022","unstructured":"Mahase E. Clinical trials: Number started in UK fell by 41% in four years, finds report. BMJ. 2022;379:o2540 https:\/\/doi.org\/10.1136\/bmj.o2540.","journal-title":"BMJ"},{"key":"3543_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S0140-6736(13)60102-6","volume":"381","author":"M Karanikolos","year":"2013","unstructured":"Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S, Stuckler D, et al. Financial crisis, austerity, and health in Europe. Lancet. 2013;381:1323\u20131331. https:\/\/doi.org\/10.1016\/S0140-6736(13)60102-6.","journal-title":"Lancet"},{"key":"3543_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-4505-13-1","volume":"13","author":"SR Hanney","year":"2015","unstructured":"Hanney SR, Castle-Clarke S, Grant J, Guthrie S, Henshall C, Mestre-Ferrandiz J, et al. How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice. Health Res Policy Syst. 2015;13:1 https:\/\/doi.org\/10.1186\/1478-4505-13-1.","journal-title":"Health Res Policy Syst"},{"key":"3543_CR12","doi-asserted-by":"publisher","first-page":"e086058","DOI":"10.1136\/bmjopen-2024-086058","volume":"14","author":"M Arora","year":"2024","unstructured":"Arora M, Kilcoyne A, Bolodeoku J, El Baghdady A. Has the UK lost its position as a destination for world-leading clinical research? A comparative analysis of haematological cancer clinical trials performance before Brexit. BMJ Open. 2024;14:e086058 https:\/\/doi.org\/10.1136\/bmjopen-2024-086058.","journal-title":"BMJ Open"},{"key":"3543_CR13","doi-asserted-by":"publisher","first-page":"14023","DOI":"10.3390\/ijerph192114023","volume":"19","author":"D Di Tonno","year":"2022","unstructured":"Di Tonno D, Perlin C, Loiacono AC, Giordano L, Martena L, Lagravinese S, et al. Trends of phase I clinical trials in the latest ten years across five European countries. Int J Environ Res Public Health. 2022;19:14023 https:\/\/doi.org\/10.3390\/ijerph192114023.","journal-title":"Int J Environ Res Public Health"},{"key":"3543_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07414-w","volume":"24","author":"A Lorenc","year":"2023","unstructured":"Lorenc A, Rooshenas L, Conefrey C, Wade J, Farrar N, Mills N, et al. Non-COVID-19 UK clinical trials and the COVID-19 pandemic: impact, challenges and possible solutions. Trials. 2023;24:424. https:\/\/doi.org\/10.1186\/s13063-023-07414-w.","journal-title":"Trials"},{"key":"3543_CR15","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.1016\/S2352-3026(20)30123-X","volume":"7","author":"Saini","year":"2020","unstructured":"Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman, M., Srinivasan, G., et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020;7:e432\u2013e435. https:\/\/doi.org\/10.1016\/S2352-3026(20)30123-X.","journal-title":"Lancet Haematol"},{"key":"3543_CR16","doi-asserted-by":"publisher","unstructured":"Saini KS, de las Heras B, Plummer R, Moreno V, Romano M, de Castro J, et al. Reimagining global oncology clinical trials for the postpandemic era: a call to arms. JCO Glob Oncol. 2020;1357\u20131362 https:\/\/doi.org\/10.1200\/GO.20.00346.","DOI":"10.1200\/GO.20.00346"},{"key":"3543_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07277-1","volume":"24","author":"K McDonald","year":"2023","unstructured":"McDonald K, Seltzer E, Lu M, Gaisenband SD, Fletcher C, McLeroth P, et al. Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries. Trials. 2023;24:254. https:\/\/doi.org\/10.1186\/s13063-023-07277-1.","journal-title":"Trials"},{"key":"3543_CR18","unstructured":"UK industry clinical trials: Translating actions into impact. 2025. https:\/\/www.abpi.org.uk\/publications\/uk-industry-clinical-trials-translating-actions-into-impact\/ (Accessed 13 April2026)."},{"key":"3543_CR19","unstructured":"Transforming the UK clinical research system: August 2025 update. https:\/\/www.gov.uk\/government\/publications\/transforming-the-uk-clinical-research-system-august-2025-update\/transforming-the-uk-clinical-research-system-august-2025-update (Accessed 3 April 2026)."},{"key":"3543_CR20","unstructured":"Full government response to the Lord O\u2019Shaughnessy review into commercial clinical trials. 2023. https:\/\/www.gov.uk\/government\/publications\/government-response-to-the-review-into-commercial-clinical-trials\/full-government-response-to-the-lord-oshaughnessy-review-into-commercial-clinical-trials (Accessed 3 April 2026)."},{"key":"3543_CR21","unstructured":"Research Delivery Network. NIHR. 2024. https:\/\/www.nihr.ac.uk\/support-and-services\/support-for-delivering-research\/clinical-research-network (Accessed 3 April 2026)."},{"key":"3543_CR22","doi-asserted-by":"publisher","first-page":"e096206","DOI":"10.1136\/bmjopen-2024-096206","volume":"15","author":"AD Soyza","year":"2025","unstructured":"Soyza AD, Goodwin VA, Roberts K, Masoli J, Mathews J, Wilding J, et al. Rising to the challenges of research in multiple long-term conditions: health and social care research ecosystem approaches. BMJ Open. 2025;15:e096206 https:\/\/doi.org\/10.1136\/bmjopen-2024-096206.","journal-title":"BMJ Open"},{"key":"3543_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00021","volume":"2","author":"JM Unger","year":"2025","unstructured":"Unger JM, Andrews HS, Levit LA, McKelvey BA, Stewart M, Canin B, et al. Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies. JCO Oncol Adv. 2025;2:e2500021. https:\/\/doi.org\/10.1200\/OA-25-00021.","journal-title":"JCO Oncol Adv"},{"key":"3543_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1162\/qss_a_00354","volume":"6","author":"W Zhao","year":"2025","unstructured":"Zhao W, Yuan C, He Z, Du J. Measuring the impact of the COVID-19 pandemic on the activeness, efficiency, and international collaboration of clinical trials. Quant Sci Stud. 2025;6:375\u2013404. https:\/\/doi.org\/10.1162\/qss_a_00354.","journal-title":"Quant Sci Stud"},{"key":"3543_CR25","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41591-025-03926-x","volume":"31","author":"R Casolino","year":"2025","unstructured":"Casolino R, Tatah L, Charnaud S, Santero M, Ilbawi A, Ross AL. The WHO global landscape of cancer clinical trials. Nat Med. 2025;31:2901\u20132912. https:\/\/doi.org\/10.1038\/s41591-025-03926-x.","journal-title":"Nat Med"},{"key":"3543_CR26","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.230832","volume":"11","author":"L Kratochv\u00edl","year":"2024","unstructured":"Kratochv\u00edl L, Havl\u00ed\u010dek J. The fallacy of global comparisons based on per capita measures. R Soc Open Sci. 2024;11:230832. https:\/\/doi.org\/10.1098\/rsos.230832.","journal-title":"R Soc Open Sci"},{"key":"3543_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100647","volume":"46","author":"M Lawler","year":"2025","unstructured":"Lawler M, Bhatti S, Przewiezlikowski P, Wolf B, Fr\u0105tczak-Kazana J, Rutkowski P, et al. Central and Eastern Europe: a crucible for clinical cancer innovation?. J Cancer Policy. 2025;46:100647. https:\/\/doi.org\/10.1016\/j.jcpo.2025.100647.","journal-title":"J Cancer Policy"},{"key":"3543_CR28","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharmaceutica Sin B. 2022;12:4365\u20134377. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.004.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"3543_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cai2.58","volume":"2","author":"Y Cao","year":"2023","unstructured":"Cao Y, Ye L, Fan Z, Yang W, Chen L, Mei Y, et al. The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010\u20132019). Cancer Innov. 2023;2:79\u201390. https:\/\/doi.org\/10.1002\/cai2.58.","journal-title":"Cancer Innov"},{"key":"3543_CR30","doi-asserted-by":"publisher","unstructured":"Fan R, Zheng Y, Zhou R, Beeraka NM, Sukocheva OA, Zhao R, et al. Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories. Front Med. 2023;10: https:\/\/doi.org\/10.3389\/fmed.2023.1203346.","DOI":"10.3389\/fmed.2023.1203346"},{"key":"3543_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.4143\/crt.2024.128","volume":"56","author":"H Ha","year":"2024","unstructured":"Ha H, Lee HY, Kim JH, Kim DY, An HJ, Bae S, et al. Precision oncology clinical trials: a systematic review of phase II clinical trials with biomarker-driven, adaptive design. Cancer Res Treat. 2024;56:991\u20131013. https:\/\/doi.org\/10.4143\/crt.2024.128.","journal-title":"Cancer Res Treat"},{"key":"3543_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jadpro.2023.14.3.16","volume":"14","author":"DC Moore","year":"2023","unstructured":"Moore DC, Guinigundo AS. Biomarker-driven oncology clinical trials: novel designs in the era of precision medicine. J Adv Pr Oncol. 2023;14:9\u201313. https:\/\/doi.org\/10.6004\/jadpro.2023.14.3.16.","journal-title":"J Adv Pr Oncol"},{"key":"3543_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3322\/caac.21880","volume":"75","author":"M Nikanjam","year":"2025","unstructured":"Nikanjam M, Kato S, Allen T, Sicklick JK, Kurzrock R. Novel clinical trial designs emerging from the molecular reclassification of cancer. CA Cancer J Clin. 2025;75:243\u2013267. https:\/\/doi.org\/10.3322\/caac.21880.","journal-title":"CA Cancer J Clin"},{"key":"3543_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/CCO.0b013e32835ff3cb","volume":"25","author":"R Dienstmann","year":"2013","unstructured":"Dienstmann R, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol. 2013;25:305\u2013312. https:\/\/doi.org\/10.1097\/CCO.0b013e32835ff3cb.","journal-title":"Curr Opin Oncol"},{"key":"3543_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/PPO.0000000000000383","volume":"25","author":"A Mittra","year":"2019","unstructured":"Mittra A, Moscow JA. Future approaches to precision oncology-based clinical trials. Cancer J. 2019;25:300\u2013304. https:\/\/doi.org\/10.1097\/PPO.0000000000000383.","journal-title":"Cancer J"},{"key":"3543_CR36","unstructured":"Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC Text with EEA relevance. 2014. https:\/\/eur-lex.europa.eu\/eli\/reg\/2014\/536\/oj\/eng (Accessed on 16 April 2026)."},{"key":"3543_CR37","unstructured":"Clinical trials for medicines: manage your authorisation, report safety issues. 2014. https:\/\/www.gov.uk\/guidance\/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues (Accessed 14 April 2026)."},{"key":"3543_CR38","unstructured":"Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - final report. 2023. https:\/\/www.gov.uk\/government\/publications\/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review\/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review-final-report (Accessed 13 April 2026)."},{"key":"3543_CR39","unstructured":"MHRA performance data for assessment of clinical trials and established medicines. 2025. https:\/\/www.gov.uk\/government\/publications\/mhra-performance-data-for-assessment-of-clinical-trials-and-established-medicines (Accessed 8 April 2026)."},{"key":"3543_CR40","unstructured":"The approvals process for applications. 2026. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/clinical-trial-regulations-reform\/guidance-on-changes-to-the-clinical-trials-regulations\/the-approvals-process-for-clinical-trials\/the-approvals-process-for-applications\/ (Accessed 8 April 2026)."},{"key":"3543_CR41","unstructured":"Inclusion and exclusion criteria for automatic authorisation. 2026. https:\/\/assets.publishing.service.gov.uk\/media\/69e64bdb44a079b27f997fb7\/Tab1._Inclusion_and_exclusion_criteria_for_automatic_authorisation.pdf (Accessed on 16 April 2026)."},{"key":"3543_CR42","unstructured":"The Medicines for Human Use (Clinical Trials) (Amendment) Regulations. 2025. https:\/\/www.legislation.gov.uk\/uksi\/2025\/538\/introduction (Accessed 16 April 2026)."},{"key":"3543_CR43","unstructured":"UK clinical trial approval times twice as fast with AI and reforms. 2025. https:\/\/www.gov.uk\/government\/news\/uk-clinical-trial-approval-times-twice-as-fast-with-ai-and-reforms (Accessed 16 April 2026)."},{"key":"3543_CR44","unstructured":"Prime Minister turbocharges medical research. 2025. https:\/\/www.gov.uk\/government\/news\/prime-minister-turbocharges-medical-research (Accessed 10 April 2026)."},{"key":"3543_CR45","doi-asserted-by":"publisher","first-page":"q2812","DOI":"10.1136\/bmj.q2812","volume":"387","author":"J Wise","year":"2024","unstructured":"Wise J. Clinical trials: New UK framework aims to streamline process and improve transparency. BMJ. 2024;387:q2812 https:\/\/doi.org\/10.1136\/bmj.q2812.","journal-title":"BMJ"},{"key":"3543_CR46","unstructured":"10 Year Health Plan for England: fit for the future. 2025. https:\/\/www.gov.uk\/government\/publications\/10-year-health-plan-for-england-fit-for-the-future (Accessed 13 April 2026)."},{"key":"3543_CR47","unstructured":"Building a faster, more effective clinical trials system. 2025. https:\/\/www.gov.uk\/government\/news\/building-a-faster-more-effective-clinical-trials-system (Accessed 8 April 2026)."},{"key":"3543_CR48","unstructured":"Life Sciences Growth Package - Hansard - UK Parliament. 2023. https:\/\/hansard.parliament.uk\/commons\/2023-06-05\/debates\/23060565000011\/LifeSciencesGrowthPackage (Accessed 9 April 2026)."},{"key":"3543_CR49","unstructured":"Horizon Europe funding. 2021. https:\/\/www.gov.uk\/business-finance-support\/horizon-europe-funding (Accessed 16 April 2026)."},{"key":"3543_CR50","doi-asserted-by":"publisher","unstructured":"Cook JA, Costa ML. UK clinical trials are under pressure. 2025; https:\/\/doi.org\/10.1136\/bmj.r1883.","DOI":"10.1136\/bmj.r1883"},{"key":"3543_CR51","unstructured":"Clinical trials regulations reform. 2026. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/clinical-trial-regulations-reform\/ (Accessed 16 April 2026)."},{"key":"3543_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/19466315.2024.2308882","volume":"17","author":"MA Schepps","year":"2025","unstructured":"Schepps MA, Wong WK, Austin M, Anisimov V. Optimizing patient recruitment in global clinical trials using nature-inspired metaheuristics. Stat Biopharmaceutical Res. 2025;17:87\u2013101. https:\/\/doi.org\/10.1080\/19466315.2024.2308882.","journal-title":"Stat Biopharmaceutical Res"},{"key":"3543_CR53","unstructured":"Cancer: develop treatments and diagnostic technologies in the UK. 2019. https:\/\/www.gov.uk\/government\/publications\/cancer-develop-treatments-and-diagnostic-technologies-in-the-uk\/cancer-develop-treatments-and-diagnostic-technologies-in-the-uk (Accessed 16 April 2026)."},{"key":"3543_CR54","unstructured":"Importing investigational medicinal products (IMP) from countries on a list to Great Britain. 2025. https:\/\/www.gov.uk\/government\/publications\/importing-investigational-medicinal-products-into-great-britain-from-approved-countries\/importing-investigational-medicinal-products-imp-from-countries-on-a-list-to-great-britain (Accessed 16 April 2026)."},{"key":"3543_CR55","unstructured":"United Kingdom: MHRA Issues Guidance for Clinical Trials Post-Brexit Transition Period. ClinRegs. 2026. https:\/\/clinregs.niaid.nih.gov\/updates\/full\/44-united-kingdom%3A-mhra-issues-guidance-for-clinical-trials-post-brexit-transition-period (Accessed 16 April 2026)."},{"key":"3543_CR56","unstructured":"Clinical Trials of Investigational Medicinal Products (CTIMPs). 2026. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/ (Accessed 9 April 2026)."},{"key":"3543_CR57","unstructured":"The Importance of Clinical Trial Transparency and FDA Oversight. FDA. 2023. https:\/\/www.fda.gov\/news-events\/fda-voices\/importance-clinical-trial-transparency-and-fda-oversight (Accessed 9 April 2026)."},{"key":"3543_CR58","unstructured":"Commercial study set up times reduced by a third. NIHR. 2023. https:\/\/www.nihr.ac.uk\/news\/commercial-study-set-times-reduced-third (Accessed 9 April 2026)."},{"key":"3543_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01359-x","volume":"21","author":"A Bl\u00fcmle","year":"2021","unstructured":"Bl\u00fcmle A, Wollmann K, Bischoff K, Kapp P, Lohner S, Nury E, et al. Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT). BMC Med Res Methodol. 2021;21:182. https:\/\/doi.org\/10.1186\/s12874-021-01359-x.","journal-title":"BMC Med Res Methodol"},{"key":"3543_CR60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41392-025-02267-y","volume":"10","author":"R Tan","year":"2025","unstructured":"Tan R, Hua H, Zhou S, Yang Z, Yang C, Huang G, et al. Current landscape of innovative drug development and regulatory support in China. Sig Transduct Target Ther. 2025;10:220 https:\/\/doi.org\/10.1038\/s41392-025-02267-y.","journal-title":"Sig Transduct Target Ther"},{"key":"3543_CR61","unstructured":"APBI. The road to recovery for UK industry clinical trials. 2024. https:\/\/www.abpi.org.uk\/media\/eyzpflm5\/abpi-the-road-to-recovery-for-uk-industry-clinical-trials-december-2024.pdf (Accessed 16 April 2026)."},{"key":"3543_CR62","unstructured":"Globally competitive UK-wide data-enabled clinical trials: the time is now. 2026. https:\/\/www.abpi.org.uk\/publications\/globally-competitive-uk-wide-data-enabled-clinical-trials-the-time-is-now\/ (Accessed 8 April 2026)."},{"key":"3543_CR63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0141076820961776","volume":"114","author":"MJ Calvert","year":"2021","unstructured":"Calvert MJ, Marston E, Samuels M, Rivera SC, Torlinska B, Oliver K, et al. Advancing UK regulatory science and innovation in healthcare. J R Soc Med. 2021;114:5\u201311. https:\/\/doi.org\/10.1177\/0141076820961776.","journal-title":"J R Soc Med"},{"key":"3543_CR64","unstructured":"International Recognition Procedure. 2026. https:\/\/www.gov.uk\/government\/publications\/international-recognition-procedure\/international-recognition-procedure (Accessed 16 April 2026)."},{"key":"3543_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1011082","volume":"9","author":"MP Hofer","year":"2022","unstructured":"Hofer MP, Criscuolo P, Shah N, Ter Wal ALJ, Barlow J. Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: initial insights. Front Med. 2022;9:1011082. https:\/\/doi.org\/10.3389\/fmed.2022.1011082.","journal-title":"Front Med"},{"key":"3543_CR66","unstructured":"Rescuing patient access to industry clinical trials in the UK. 2022. https:\/\/www.abpi.org.uk\/publications\/rescuing-the-uk-industry-clinical-trials\/ (Accessed 16 April 2026)."},{"key":"3543_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1246682","volume":"14","author":"B Wang","year":"2023","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682. https:\/\/doi.org\/10.3389\/fimmu.2023.1246682.","journal-title":"Front Immunol"},{"key":"3543_CR68","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","volume":"75","author":"W Sadee","year":"2023","unstructured":"Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharm Rev. 2023;75:789\u2013814. https:\/\/doi.org\/10.1124\/pharmrev.122.000810.","journal-title":"Pharm Rev"},{"key":"3543_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100. https:\/\/doi.org\/10.1038\/s41571-020-0426-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"3543_CR70","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5:1351\u20131377. https:\/\/doi.org\/10.1016\/j.medj.2024.08.010.","journal-title":"Med"},{"key":"3543_CR71","unstructured":"EMA Guideline on Quality, non-clinical and clinical Requirements for Investigational Medicinal Products for Advanced Therapies in Clinical Trials - ECA Academy. 2025. https:\/\/www.gmp-compliance.org\/gmp-news\/ema-guideline-on-quality-non-clinical-and-clinical-requirements-for-investigational-medicinal-products-for-advanced-therapies-in-clinical-trials (Accessed 8 April 2026)."},{"key":"3543_CR72","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/17460751.2024.2427505","volume":"19","author":"R Chandaria","year":"2024","unstructured":"Chandaria R, Rice P, Baston D, Willingham F, Barry J. ATMP clinical trials in the UK. Regen Med. 2024;19:541\u2013548. https:\/\/doi.org\/10.1080\/17460751.2024.2427505.","journal-title":"Regen Med"},{"key":"3543_CR73","unstructured":"Innovative Licensing and Access Pathway (ILAP). 2025. https:\/\/www.gov.uk\/government\/publications\/innovative-licensing-and-access-pathway-ilap (Accessed 14 April 2026)."},{"key":"3543_CR74","unstructured":"UK Clinical Research Network (UKCRN) | UKCRC. 2005. http:\/\/www.ukcrc.org\/research-infrastructure\/clinical-research-networks\/uk-clinical-research-network-ukcrn\/ (Accessed 14 April 2026)."},{"key":"3543_CR75","unstructured":"The Advanced Therapy Treatment Centre (ATTC) Network. 2026. https:\/\/www.theattcnetwork.co.uk\/ (Accessed 13 April 2026)."},{"key":"3543_CR76","doi-asserted-by":"publisher","unstructured":"Cell and gene therapies could save NHS billions. Pharmaceutical J. 2025; https:\/\/doi.org\/10.1211\/PJ.2025.1.380687.","DOI":"10.1211\/PJ.2025.1.380687"},{"key":"3543_CR77","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1016\/j.vaccine.2019.09.009","volume":"37","author":"RJ Noad","year":"2019","unstructured":"Noad RJ, Simpson K, Fooks AR, Hewson R, Gilbert SC, Stevens MP, et al. UK vaccines network: mapping priority pathogens of epidemic potential and vaccine pipeline developments. Vaccine. 2019;37:6241\u20136247. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.009.","journal-title":"Vaccine"},{"key":"3543_CR78","doi-asserted-by":"publisher","first-page":"e072491","DOI":"10.1136\/bmjopen-2023-072491","volume":"13","author":"N Mackillop","year":"2023","unstructured":"Mackillop N, Shah J, Collins M, Costelloe T, \u00d6hman D. Carbon footprint of industry-sponsored late-stage clinical trials. BMJ Open. 2023;13:e072491 https:\/\/doi.org\/10.1136\/bmjopen-2023-072491.","journal-title":"BMJ Open"},{"key":"3543_CR79","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/ced\/llad099","volume":"48","author":"E Edache","year":"2023","unstructured":"Edache E, Seeley B, Johnson-Ogbuneke J, Hailston L, Moiz H, Madhwapathi V, et al. Call for a standardized environmental sustainability checklist for reporting clinical research. Clin Exp Dermatol. 2023;48:704\u2013706. https:\/\/doi.org\/10.1093\/ced\/llad099.","journal-title":"Clin Exp Dermatol"},{"key":"3543_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08083-z","volume":"25","author":"E Piltonen","year":"2024","unstructured":"Piltonen E, Goulao B, Gillies K. Designing greener participant-centred trials: an analysis of \u2018carbon relevant\u2019 factors within items that influence participants\u2019 decisions about trial recruitment and retention. Trials. 2024;25:260. https:\/\/doi.org\/10.1186\/s13063-024-08083-z.","journal-title":"Trials"},{"key":"3543_CR81","unstructured":"Step by step guide to using IRAS for combined review. 2026. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/combined-review\/step-step-guide-using-iras-combined-ways-working-cwow\/ (Accessed 14 April 2026)."},{"key":"3543_CR82","unstructured":"Performance Metrics-Assessment of Clinical Trial Authorisation Applications and Substantial Amendments. 2022. https:\/\/assets.publishing.service.gov.uk\/media\/65f83bfcfc7fcf001ac6481c\/CT-Performance-Metrics_2208-2307-new.pdf. (Accessed 16 April 2026)."},{"key":"3543_CR83","unstructured":"MHRA Performance Data. MHRA Performance Data. 2026. https:\/\/www.gov.uk\/government\/publications\/mhra-performance-data\/mhra-performance-data (Accessed 16 April 2026)."},{"key":"3543_CR84","doi-asserted-by":"publisher","unstructured":"Manfrin A, Lee K, Cacou C, Pound J, Harnden A, Raine J, et al. Evaluation of the Medicines and Healthcare products Regulatory Agency\u2019s introduction of a risk-proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024. Br J Clin Pharmacol. 2025;bcp.70308 https:\/\/doi.org\/10.1002\/bcp.70308.","DOI":"10.1002\/bcp.70308"},{"key":"3543_CR85","doi-asserted-by":"publisher","unstructured":"Husain M. Clinical research in the UK is failing: universities and NHS trusts need to change. BMJ. 2025;r469 https:\/\/doi.org\/10.1136\/bmj.r469.","DOI":"10.1136\/bmj.r469"},{"key":"3543_CR86","unstructured":"The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024. 2024. https:\/\/www.legislation.gov.uk\/ukdsi\/2024\/9780348267167 (Accessed 5 April 2026)."},{"key":"3543_CR87","unstructured":"Sponsor handbook Clinical Trial Information System (CTIS) user guidance on the sponsor\u2019s workspace. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/other\/clinical-trial-information-system-ctis-sponsor-handbook_en.pdf (Accessed on 5 April 2026)."},{"key":"3543_CR88","unstructured":"Launch of revised CTIS transparency rules - Accelerating Clinical Trials in the EU. 2024. https:\/\/accelerating-clinical-trials.europa.eu\/newsroom\/news\/launch-revised-ctis-transparency-rules-2024-04-22_en (Accessed 5 April 2026)."},{"key":"3543_CR89","unstructured":"Revised transparency rules for the EU Clinical Trials Information System (CTIS) | European Medicines Agency (EMA). 2023. https:\/\/www.ema.europa.eu\/en\/news\/revised-transparency-rules-eu-clinical-trials-information-system-ctis (Accessed 5 April 2026)."},{"key":"3543_CR90","unstructured":"United States: National Archives and Records Administration: Office of the Federal Register. An act to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the post market authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. 2007. https:\/\/www.govinfo.gov\/app\/details\/PLAW-110publ85\/summary (Accessed 9 April 2026)."},{"key":"3543_CR91","unstructured":"Clinical trials - Directive 2001\/20\/EC - Public Health. 2025. https:\/\/health.ec.europa.eu\/medicinal-products\/clinical-trials\/clinical-trials-directive-200120ec_en (Accessed 9 April 2026)."},{"key":"3543_CR92","unstructured":"Monthly UK clinical research update. 2026. https:\/\/sites.google.com\/nihr.ac.uk\/thefutureofukclinicalresearch\/home\/news-updates\/monthly-uk-clinical-research-update (Accessed 9 April 2026)."},{"key":"3543_CR93","unstructured":"Good Clinical Practice. 2020. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/good-clinical-practice\/ (Accessed 9 April 2026)."},{"key":"3543_CR94","unstructured":"Clinical trials for medicines: collection, verification, & reporting of safety events. 2025. https:\/\/www.gov.uk\/guidance\/clinical-trials-for-medicines-collection-verification-reporting-of-safety-events (Accessed 9 April 2026)."},{"key":"3543_CR95","unstructured":"General Data Protection Regulation (GDPR) \u2013 Legal Text. 2018. https:\/\/gdpr-info.eu\/ (Accessed 9 April 2026)."},{"key":"3543_CR96","unstructured":"Clinical Research Regulation For United Kingdom. ClinRegs. 2025. https:\/\/clinregs.niaid.nih.gov\/country\/united-kingdom#data_&_records_management (Accessed 9 April 2026)."},{"key":"3543_CR97","unstructured":"Medicines: clinical trials hub. 2023. https:\/\/www.gov.uk\/government\/collections\/medicines-clinical-trials (Accessed 9 April 2026)."},{"key":"3543_CR98","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41416-019-0653-9","volume":"122","author":"SP Blagden","year":"2020","unstructured":"Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, et al. Effective delivery of Complex Innovative Design (CID) cancer trials\u2014a consensus statement. Br J Cancer. 2020;122:473\u2013482. https:\/\/doi.org\/10.1038\/s41416-019-0653-9.","journal-title":"Br J Cancer"},{"key":"3543_CR99","unstructured":"Guidance on changes to the clinical trials regulations. 2026. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/clinical-trial-regulations-reform\/guidance-on-changes-to-the-clinical-trials-regulations\/ (Accessed 17 April 2026)."},{"key":"3543_CR100","unstructured":"Investing in infrastructure. NIHR. 2026. https:\/\/www.nihr.ac.uk\/about-us\/what-we-do\/infrastructure (Accessed 17 April 2026)."},{"key":"3543_CR101","unstructured":"Parker B, Moulton G. Workforce Development and Capacity Building. Workforce Development and Capacity Building. 2023. https:\/\/www.manchesterbrc.nihr.ac.uk\/wp-content\/uploads\/2023\/10\/Training-and-Capacity-Building-George-Moulton-and-Ben-Parker.pdf (Accessed 5 April 2026)."},{"key":"3543_CR102","unstructured":"NIHR Annual Report 2023\/24. NIHR. 2024. https:\/\/www.nihr.ac.uk\/about-us\/who-we-are\/reports-and-performance\/annual-report-202324 (Accessed 17 April 2026)."},{"key":"3543_CR103","unstructured":"UKRI. Global health. 2026. https:\/\/www.ukri.org\/what-we-do\/browse-our-areas-of-investment-and-support\/applied-global-health\/ (Accessed 5 Aprl 2026)."},{"key":"3543_CR104","unstructured":"Getting back on track: Restoring the UK\u2019s global position in industry clinical trials. 2023. https:\/\/www.abpi.org.uk\/publications\/getting-back-on-track-restoring-the-uk-s-global-position-in-industry-clinical-trials\/ (Accessed 3 April 2026)."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03543-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:02:00Z","timestamp":1791270120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["3543"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03543-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PC-F, AM, LV, DM, MN, JB, SD, VB, CJ, SC, MG, and KSS are employees of Fortrea Inc. SPB is co-founder and Director of Prenostics Ltd. VB reports stock ownership interests in Fortrea Inc. TRJE has received travel expenses from Bristol-Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Eisai, Nucana, and Roche. His institution has received consulting fees and\/or speaker fees\/honoraria and\/or research funding from Karus Therapeutics, Eisai, Bristol-Myers Squibb, Merck Sharp & Dohme, United Medical, Nucana, Roche\/Genentech, Ascelia, AstraZeneca, Bicycle Therapeutics, Medivir, Seagen, CV6 Therapeutics, Ewopharma, iOnctura, Beigene, Basilea, Celgene, MiNA Therapeutics, Lilly, Merck Serono, Janssen, Johnson & Johnson, Verastem, Novartis, Iovance Biotherapeutics, Sanofi\/Aventis, Clovis Oncology, Plexxikon, Sierra Pharma, GlaxoSmithKline, Halozyme, CytomX Therapeutics, Vertex, Athenex, Adaptimmune, Immunocore, Modulate Pharma, Berg, Starpharma, BiolineRx, UCB, Sapience Therapeutics, Astellas Pharma, Boehringer Ingelheim, Avacta Life Sciences, Nurix, Codiak BioSciences, T3 Pharmaceuticals, BioNTech, Moderna Therapeutics, Exelixis, Exscientia, Bayer, Amgen, Sotio, and Pfizer. His institution also received honoraria from Genmab for serving as Chair of the Independent Data Monitoring Committee for a phase 1 trial. He is also Editor-in-Chief of The British Journal of Cancer. KSS reports consulting fees from the EU Commission and stock and\/or other ownership interests in Fortrea Inc. and Quantum Health Analytics (UK) Ltd, outside the submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}